[ { "abstract_id": "OR1-1_104404", "title": "OR1-1 | Machine Learning-Enhanced Prediction of Acute Kidney Injury Following Percutaneous Coronary Intervention: An Analysis of the MIMIC-IV Database", "clean_title": "Machine Learning-Enhanced Prediction of Acute Kidney Injury Following Percutaneous Coronary Intervention: An Analysis of the MIMIC-IV Database", "conference": "Journal of the Society for Cardiovascular Angiography & Interventions", "conference_event": "SCAI 2026 Scientific Sessions (Montreal, April 23-26, 2026)", "doi_or_url": "https://doi.org/10.1016/j.jscai.2026.104404", "authors": [ "Masab Mansoor" ], "publication_date": "2026-04", "full_text": "Background: Acute Kidney Injury (AKI) is a significant complication following Percutaneous Coronary Intervention (PCI), particularly in critically ill populations. Traditional risk stratification often relies on linear assumptions that may underestimate risk in complex patients. We sought to develop and validate a machine learning (ML) model using the MIMIC-IV critical care database to predict post-PCI AKI with greater accuracy than conventional logistic regression. Methods: We performed a retrospective study utilizing the MIMIC-IV v2.2 database. Patients ≥18 years undergoing PCI (2008–2019) were identified using ICD/CPT procedure codes. The primary outcome was AKI within 48 hours, defined by KDIGO criteria. We extracted 38 features, including admission vitals, laboratories, and comorbidities. The dataset was split into training (80%) and testing (20%) sets. An Extreme Gradient Boosting (XGBoost) model was trained with 5-fold cross-validation and compared to multivariable logistic regression (LR) using the Area Under the Receiver Operating Characteristic curve (AUC). Results: The cohort included 4,128 patients (mean age 68.4$\\pm$12.1 years; 31.2% female). The overall AKI incidence was 14.3% (n=590). In the independent test set, the XGBoost model achieved an AUC of 0.84 (95% CI: 0.81–0.87), significantly outperforming the logistic regression model (AUC 0.73; p<0.001). The ML model demonstrated superior sensitivity (76% vs. 62%) at matched specificity levels. Feature importance analysis identified admission lactate, BUN, and RDW as top predictors, distinct from static risk factors like age./ Conclusions: In this large analysis of critically ill patients undergoing PCI, a gradient-boosting ML model significantly outperformed conventional statistical methods in predicting acute kidney injury. Integrating such models into electronic health records could facilitate automated risk stratification and trigger targeted preventive strategies for high-risk patients.", "source_page_url": "https://www.jscai.org/issue/S2772-9303(26)X2005-1", "status": "PASS", "text_source": "confex", "session_code": "OR1-1", "page_number": 104404 }, { "abstract_id": "OR1-2_104405", "title": "OR1-2 | One-Year Outcomes of Coronary Stenting Versus Conservative Management in Spontaneous Coronary Artery Dissection", "clean_title": "One-Year Outcomes of Coronary Stenting Versus Conservative Management in Spontaneous Coronary Artery Dissection", "conference": "Journal of the Society for Cardiovascular Angiography & Interventions", "conference_event": "SCAI 2026 Scientific Sessions (Montreal, April 23-26, 2026)", "doi_or_url": "https://doi.org/10.1016/j.jscai.2026.104405", "authors": [ "Ali Awad", "Qusai Alqudah", "Ali Alramadan", "Edidiong okon Ben", "M Chadi Alraies" ], "publication_date": "2026-04", "full_text": "Background Optimal management of spontaneous coronary artery dissection (SCAD) remains debated. While conservative therapy is generally preferred, coronary stenting is frequently used in selected cases. Comparative outcome data remain limited. Methods Using the TriNetX network, we identified patients with SCAD managed with coronary stenting or conservative therapy. Propensity score matching yielded 389 patients per group with balanced baseline characteristics. Outcomes were assessed at 30 days and 1 year. Results At 30 days, all-cause mortality was low and similar between stenting and conservative management (2.6% vs 2.6%, p=0.99). At 1 year, all-cause mortality remained comparable (4.9% vs 4.1%; HR 1.20, 95% CI 0.62–2.34; p=0.59). Among patients without prior events, stenting was associated with higher rates of major adverse cardiovascular events (23.2% vs 11.5%; HR 2.21, 95% CI 1.12–4.38; p=0.025) and recurrent myocardial infarction (21.1% vs 7.4%; HR 3.09, 95% CI 1.44–6.60; p=0.0026). Kaplan–Meier analysis demonstrated significantly lower event-free survival in the stenting group. Conclusions In a propensity-matched SCAD cohort, coronary stenting was not associated with improved survival and was linked to higher long-term ischemic events compared with conservative management. These findings support conservative therapy when clinically feasible and emphasize careful patient selection for PCI in SCAD.", "source_page_url": "https://www.jscai.org/issue/S2772-9303(26)X2005-1", "status": "PASS", "text_source": "confex", "session_code": "OR1-2", "page_number": 104405 }, { "abstract_id": "OR1-3_104406", "title": "OR1-3 | Emerging Role of Neurovascular Stent Retrievers in STEMI With High Thrombus Burden: A Systematic Review of Reperfusion and Safety Outcomes", "clean_title": "Emerging Role of Neurovascular Stent Retrievers in STEMI With High Thrombus Burden: A Systematic Review of Reperfusion and Safety Outcomes", "conference": "Journal of the Society for Cardiovascular Angiography & Interventions", "conference_event": "SCAI 2026 Scientific Sessions (Montreal, April 23-26, 2026)", "doi_or_url": "https://doi.org/10.1016/j.jscai.2026.104406", "authors": [ "Vani Malhotra", "Hema Gedela", "Mohammed Amaanullah", "Siddhi Shah", "Aayushi M. Mehta", "Somnath Panda", "Oluwasolabomi Onadipe", "Sara Hazaveh", "Ridhinayani Nalam", "Maanya Rajasree Katta", "Muhammad Raza Sarfraz", "Prakyath Kothari", "Hruthvik Bojja" ], "publication_date": "2026-04", "full_text": "Background High thrombus burden in STEMI complicates primary PCI and is associated with distal embolization, no-reflow, and impaired myocardial perfusion. Manual aspiration thrombectomy has not demonstrated consistent benefit and is no longer routinely recommended, leaving limited mechanical options. New-generation stent retrievers, adapted from neurovascular thrombectomy, allow en bloc thrombus extraction and may improve reperfusion in selected high-risk STEMI cases, though evidence remains limited. Methods We performed PRISMA-guided systematic review of PubMed, Embase, Cochrane, Scopus, Web of Science, ClinicalTrials.gov (2015–2025); included RCTs, cohorts, case reports; excluded reviews, editorials. Primary outcomes: TIMI-3 flow, MBG, thrombus removal; Secondary: MACE, complications, in-hospital mortality. Results Twelve studies (1 RCT, 2 cohorts, 9 case reports) met inclusion. Solitaire X achieved TIMI-3 flow 81.4% vs 62.9% with PCI alone; Myocardial blush grade 3 was 77.7% vs 48.1%. No MACE with Solitaire X vs one in each comparator. NeVa (n=15, n=61) showed 86.6% to 98.1% TIMI-3 flow with rare complications (<5%). Case reports (ERIC, NeVa, Solitaire AB/X, EnVast, hybrids) showed 100% reperfusion, no deaths, minor complications. Conclusions In high thrombus burden STEMI, new-generation coronary stent retrievers are associated with high rates of complete reperfusion and favorable short-term safety compared with standard PCI strategies. These findings support further investigation in multicenter randomized trials to define their role in contemporary STEMI practice.", "source_page_url": "https://www.jscai.org/issue/S2772-9303(26)X2005-1", "status": "PASS", "text_source": "confex", "session_code": "OR1-3", "page_number": 104406 }, { "abstract_id": "OR1-4_104407", "title": "OR1-4 | Impact of Hospital Location and Teaching Status on Outcomes of Acute Myocardial Infarction Complicated by Cardiac Arrest: A Nationwide Retrospective Study", "clean_title": "Impact of Hospital Location and Teaching Status on Outcomes of Acute Myocardial Infarction Complicated by Cardiac Arrest: A Nationwide Retrospective Study", "conference": "Journal of the Society for Cardiovascular Angiography & Interventions", "conference_event": "SCAI 2026 Scientific Sessions (Montreal, April 23-26, 2026)", "doi_or_url": "https://doi.org/10.1016/j.jscai.2026.104407", "authors": [ "Roopeessh Vempati", "Andrew Gregory", "Mohammad Ali Sheffeh", "Karamdev Singh Grewal", "Rafat Dallo", "Ibrahim Mohammed", "Khaled Elnaggar", "Fawaz Mohammed", "M Chadi Alraies" ], "publication_date": "2026-04", "full_text": "Background While timely reperfusion and mechanical circulatory support (MCS) are central to the management of acute MI complicated by cardiac arrest (AMI-CA), utilization patterns and outcomes may vary according to hospital location and teaching status. Methods We analyzed 128,035 adult AMI-CA hospitalizations (2018–2022, National Inpatient Sample). Hospitals were categorized as rural(R), urban non-teaching (UNT), or urban teaching(UT). The trends were analyzed, and multivariate regression was conducted to evaluate the outcomes. P <0.05 was considered to be statistically significant. Results Overall, in-hospital mortality was 40.9%, with regional differences [R 43.1%, UNT 41.8%, UT 40.6%]. Adjusted analyses showed higher odds of mortality in UNT compared with rural hospitals (OR 1.09, p=0.006), while UT hospitals showed no significant difference. PCI utilization increased across all hospital types, with the highest rates in UT centers (49.5%─2019, 45.2%─2022). PCI use was significantly greater in UNT (OR 1.15, p<0.001) and UT hospitals (OR 1.07, p=0.02). IABP utilization was lower in UNT (OR 0.85, p <0.001) and UT hospitals (OR 0.86, p <0.001). Percutaneous left ventricular assist device (pLVAD) and ECMO were markedly more utilized in UT centers (pLVAD OR 2.05, p <0.001; ECMO OR 4.48, p <0.001), with pLVAD also more common in UNT hospitals (OR 1.69, p <0.001). Conclusions Rural hospitals demonstrated higher mortality and lower advanced MCS utilization, while UT hospitals had greater adoption of pLVAD and ECMO but no mortality advantage.", "source_page_url": "https://www.jscai.org/issue/S2772-9303(26)X2005-1", "status": "PASS", "text_source": "confex", "session_code": "OR1-4", "page_number": 104407 }, { "abstract_id": "OR1-5_104408", "title": "OR1-5 | Bleeding Risk in Patients with Chronic Kidney Disease Receiving Cangrelor for Acute Myocardial Infarction: Results from the CAMEO Registry", "clean_title": "Bleeding Risk in Patients with Chronic Kidney Disease Receiving Cangrelor for Acute Myocardial Infarction: Results from the CAMEO Registry", "conference": "Journal of the Society for Cardiovascular Angiography & Interventions", "conference_event": "SCAI 2026 Scientific Sessions (Montreal, April 23-26, 2026)", "doi_or_url": "https://doi.org/10.1016/j.jscai.2026.104408", "authors": [ "Jonathan Hanna", "Brooke Alhanti", "Courtney Page", "Deepak L. Bhatt", "Ajar Kochar", "Dominick J. Angiolillo", "Miguel A. Diaz", "Neil J. Wimmer", "Ron Waksman", "Lawrence Ang", "Richard G. Bach", "Ronald Jenkins", "Hijrah El-Sabae", "Leo Brothers", "E.M. Ohman", "Schuyler Schuyler Jones", "Jeffrey B. Washam", "Tracy Yu-Ping Wang", "Babar B. Basir", "Jennifer A. Rymer" ], "publication_date": "2026-04", "full_text": "Background Cangrelor is an intravenous P2Y12 inhibitor with a rapid onset of action and short half-life that is useful in acute myocardial infarction (MI) patients without reliable gastrointestinal access, awaiting surgery, or not pretreated with oral P2Y12 agents. Cangrelor is not renally cleared and so may be preferred in chronic kidney disease (CKD) patients but bleeding risk in this population is not well described. Methods We compared clinical characteristics by CKD (GFR< 60 mL/min/1.73m²) status in patients receiving cangrelor captured in the multicenter CAMEO registry which enrolled approximately 5,000 acute MI patients (October 2019 - June 2024) in a 2:1 ratio of cangrelor use vs. no use. The duration and dose of cangrelor was examined. The relationship between CKD status, bleeding, and MACE (in-hospital recurrent MI, stroke, death) in patients receiving cangrelor was evaluated in logistic regression models adjusted for baseline risk. Results There was a total of 5,047 patients enrolled during the study period. Of the population receiving cangrelor, 812 (24.9%) patients had CKD (median creatinine 1.5 mg/dL). These patients were older and had more extensive comorbid disease such as diabetes, prior MI, prior percutaneous coronary intervention (PCI), and prior bypass surgery (CABG; all P<0.001). There was no difference in the proportion of patients receiving glycoprotein IIb/IIIa inhibitors (3.1% vs 2.6%; P = 0.516). CKD patients received higher risk PCI with a higher proportion of left main interventions (6.9% vs 2.6%, P<0.001), mechanical circulatory support (20.1% vs 7.7%; P<0.001), thrombectomy (14.8% vs 11.5%; P = 0.015), and femoral access (44.8% vs 31.4% for no CKD; P<0.001). Cangrelor infusion durations were 18% longer in CKD patients. In logistic regression adjusted for baseline risk, CKD status was not associated with bleeding events in patients receiving cangrelor (P=0.77) but was associated with MACE (OR, 2.37; 95% CI, 1.77 – 3.18). Conclusions Acute MI patients with CKD receiving cangrelor have significant comorbidities, receive higher risk PCI, frequent femoral access, and longer cangrelor infusions. However, CKD status does not confer additional risk of bleeding in patients receiving cangrelor.", "source_page_url": "https://www.jscai.org/issue/S2772-9303(26)X2005-1", "status": "PASS", "text_source": "confex", "session_code": "OR1-5", "page_number": 104408 }, { "abstract_id": "OR1-6_104409", "title": "OR1-6 | Impact of Tirzepatide on Post-PCI Outcomes in Patients With Diabetes Mellitus: Insights From a Real-World Propensity-Matched Cohort", "clean_title": "Impact of Tirzepatide on Post-PCI Outcomes in Patients With Diabetes Mellitus: Insights From a Real-World Propensity-Matched Cohort", "conference": "Journal of the Society for Cardiovascular Angiography & Interventions", "conference_event": "SCAI 2026 Scientific Sessions (Montreal, April 23-26, 2026)", "doi_or_url": "https://doi.org/10.1016/j.jscai.2026.104409", "authors": [ "Ayodeji Ilelaboye", "Revati Varma", "Samuel Odoi", "Shreyas Nandyal", "Adrian Nubla", "Keerthana Manjunath", "Abel Tasamma", "Edith Oviri", "Marco Dispagna", "Yetunde Akande" ], "publication_date": "2026-04", "full_text": "Background Patients with diabetes mellitus (DM) undergoing percutaneous coronary intervention (PCI) remain at high risk for adverse cardiovascular outcomes. Tirzepatide, a dual GIP/GLP-1 receptor agonist, has demonstrated metabolic and cardiovascular benefits; however, its impact on post-PCI outcomes is not well defined. We evaluated the association between tirzepatide use and clinical outcomes following PCI in patients with DM Methods We conducted a retrospective cohort study using the TriNetX Network. Adult patients with DM who underwent PCI were identified and stratified by tirzepatide exposure. Propensity score matching (1:1) was performed to balance baseline characteristics, yielding 2,076 patients per cohort. Mean follow-up after matching was approximately 1 year. Outcomes included all-cause mortality, repeat myocardial infarction (MI), stroke, major adverse cardiovascular events (MACE), acute decompensated heart failure (ADHF), acute kidney injury (AKI), and in-stent restenosis (ISR). Risk ratios, hazard ratios, and Kaplan–Meier survival analyses were performed. Results After propensity matching, baseline follow-up duration was comparable between cohorts. Tirzepatide use was associated with significantly lower all-cause mortality compared with non-use (2.9% vs 7.7%; risk ratio [RR] 0.38, 95% CI 0.29–0.51; hazard ratio [HR] 0.39, 95% CI 0.29–0.52; log-rank p<0.001). Tirzepatide was also associated with reduced risks of repeat MI (18.2% vs 25.5%; HR 0.67, 95% CI 0.59–0.77), stroke (5.0% vs 7.2%; HR 0.69, 95% CI 0.54–0.89), and MACE (35.6% vs 48.7%; HR 0.66, 95% CI 0.60–0.73), all p<0.01. Additionally, tirzepatide users experienced lower rates of ADHF (39.4% vs 46.3%; HR 0.78, 95% CI 0.71–0.86), AKI (14.4% vs 21.1%; HR 0.66, 95% CI 0.57–0.77), and ISR (7.7% vs 9.9%; HR 0.78, 95% CI 0.64–0.96) Conclusions In this large, real-world, propensity-matched analysis, tirzepatide use in patients with DM undergoing PCI was associated with significantly lower all-cause mortality and reduced risks of ischemic events, heart failure, renal complications, and restenosis. These findings highlight a potential cardioprotective effect of tirzepatide in high-risk post-PCI diabetic patients.", "source_page_url": "https://www.jscai.org/issue/S2772-9303(26)X2005-1", "status": "PASS", "text_source": "confex", "session_code": "OR1-6", "page_number": 104409 }, { "abstract_id": "OR1-7_104410", "title": "OR1-7 | Impact of GLP-1 RA on Coronary Disease Progression After PCI in Obese Adults Without Diabetes: Synergy With Statin Therapy", "clean_title": "Impact of GLP-1 RA on Coronary Disease Progression After PCI in Obese Adults Without Diabetes: Synergy With Statin Therapy", "conference": "Journal of the Society for Cardiovascular Angiography & Interventions", "conference_event": "SCAI 2026 Scientific Sessions (Montreal, April 23-26, 2026)", "doi_or_url": "https://doi.org/10.1016/j.jscai.2026.104410", "authors": [ "Sultana Jahan", "Haidar Hajeh", "Mustafa Al-Mollah", "Khadeeja Sirajuddin", "Roopeessh Vempati", "Muhammad Burhan", "Seliman Ali", "Charles Danish", "Aisha Tanveer", "M Chadi Alraies" ], "publication_date": "2026-04", "full_text": "Background The role of GLP-1A receptor agonists in slowing the progression of atherosclerosis in non-diabetic obese patients undergoing percutaneous coronary intervention (PCI) remains unknown. Methods Using the TriNetX network (68 U.S. health-care organizations) we identified obese adults (BMI ≥30 kg/m²) without diabetes who underwent PCI. New GLP-1 RA prescriptions filled ≤90 days after PCI (n = 537) were propensity-matched 1:5 to non-users on age, sex, CV risk factors, and baseline statin intensity, yielding 472 matched pairs. Primary outcome was: 1-year MACE (all-cause death, MI, stroke, HF exacerbation).. Extended follow-up of up to 3 years was performed. Results At 1 year, GLP-1 RA with statins lower the risk of MACE (33.3% vs 41.3%; RR 0.81, 95% CI 0.68-0.95; p = 0.01) and admissions (31.4% vs 48.1%; RR 0.65; 95% CI 0.55-0.77; p < 0.001). Repeat PCI, MI and in-stent restenosis (ISR) did not differ; GI intolerance was more common, but hypoglycaemia/pancreatitis rare. By 3 years, MACE remained lower (36.4% vs 46.4%; RR 0.79; 95% CI (0.68, 0.92); p=0.002) and mortality halved (2.6% vs 5.5%; RR 0.46; 95% CI 0.24-0.91; p 0.02). The benefit was greatest with high-intensity statins. Conclusions Early GLP-1 RA after PCI reduces disease progression and events in obese non-diabetic adults, especially with potent statins.These findings support prospective studies to evaluate GLP-1 RA as adjunctive therapy in this population.", "source_page_url": "https://www.jscai.org/issue/S2772-9303(26)X2005-1", "status": "PASS", "text_source": "confex", "session_code": "OR1-7", "page_number": 104410 }, { "abstract_id": "OR1-8_104411", "title": "OR1-8 | Ultrathin Biodegradable-Polymer vs Durable-Polymer Drug-Eluting Stents: A Meta-Analysis of Randomized Trials", "clean_title": "Ultrathin Biodegradable-Polymer vs Durable-Polymer Drug-Eluting Stents: A Meta-Analysis of Randomized Trials", "conference": "Journal of the Society for Cardiovascular Angiography & Interventions", "conference_event": "SCAI 2026 Scientific Sessions (Montreal, April 23-26, 2026)", "doi_or_url": "https://doi.org/10.1016/j.jscai.2026.104411", "authors": [ "Afrasayab Khan", "Mah Naqshib Zargar", "Danish Zamir", "Haritha Darapaneni", "Lyluma Ishfaq", "Cleris Christian", "Sweta Sahu", "Gaurav Luthra" ], "publication_date": "2026-04", "full_text": "Background Contemporary drug-eluting stents (DES) differ by strut thickness and polymer technology. Whether ultrathin biodegradable-polymer sirolimus-eluting stents (BP-SES) provide superior clinical outcomes compared with durable-polymer everolimus-eluting stents (DP-EES) across randomized populations remains clinically relevant. Methods We performed a random-effects meta-analysis of randomized controlled trials comparing BP-SES with DP-EES in patients undergoing PCI. Trials enrolling all-comers, stable CAD, and STEMI populations were included. The primary endpoint was 1-year target lesion failure (TLF), defined as cardiac death, target-vessel myocardial infarction, or ischemia-driven target lesion revascularization. Effect estimates were pooled as risk ratios (RR) with 95% confidence intervals (CI). Heterogeneity was assessed using I². Results Three randomized trials comprising >4,000 patients were included. Across individual studies, BP-SES consistently demonstrated lower 1-year TLF compared with DP-EES. Pooled analysis showed a significant reduction in TLF with BP-SES (RR 0.68, 95% CI 0.51–0.91, p=0.008), with no observed heterogeneity (I²=0%). Absolute event rates were low in both groups. Rates of stent thrombosis and all-cause mortality were infrequent and did not differ significantly between stent platforms. Conclusions Across randomized evidence, ultrathin biodegradable-polymer sirolimus-eluting stents are associated with a significant reduction in 1-year target lesion failure compared with durable-polymer everolimus-eluting stents, with consistent effects across diverse PCI populations. These findings support stent platform selection as a modifiable procedural factor that may meaningfully influence outcomes in contemporary PCI.", "source_page_url": "https://www.jscai.org/issue/S2772-9303(26)X2005-1", "status": "PASS", "text_source": "confex", "session_code": "OR1-8", "page_number": 104411 }, { "abstract_id": "OR1-9_104412", "title": "OR1-9 | Frailty and In-Hospital Outcomes Among Older Adults With NSTEMI Undergoing PCI: A National Inpatient Sample Analysis", "clean_title": "Frailty and In-Hospital Outcomes Among Older Adults With NSTEMI Undergoing PCI: A National Inpatient Sample Analysis", "conference": "Journal of the Society for Cardiovascular Angiography & Interventions", "conference_event": "SCAI 2026 Scientific Sessions (Montreal, April 23-26, 2026)", "doi_or_url": "https://doi.org/10.1016/j.jscai.2026.104412", "authors": [ "Ider Oujamaa", "Mohammad Ali Sheffeh", "Raj K. Patel", "Amanda P. Rawson", "Zarghoona Wajid", "Naveen Vuppuluri", "Muhammad Syed", "Jelena Arnautovic", "M Chadi Alraies" ], "publication_date": "2026-04", "full_text": "Background: Frailty may worsen outcomes after NSTEMI. We examined whether frailty is independently associated with in-hospital adverse events among adults ≥65 years undergoing PCI for NSTEMI. Methods: Retrospective cohort using NIS 2016–2022. After excluding STEMI, hospitalizations without PCI, and records missing key variables, we included 462,120 NSTEMI hospitalizations among adults ≥65 years who underwent PCI. Frailty was defined by the Johns Hopkins frailty score (binary). Multivariable logistic regression adjusted for demographics, comorbidities, and hospital characteristics. Results: Mean age was 75±7 years, 38% were female, and in-hospital mortality was 2.5% (11,215 deaths). Frailty was independently associated with higher odds of in-hospital mortality (aOR 2.30, 95% CI 2.03–2.60) and multiple complications, including acute HF, AKI, stroke/TIA, bleeding, blood transfusion, vasopressor use, mechanical ventilation, cardiogenic shock, and cardiac arrest (Figure 1). Frailty was also associated with increased use of IABP (aOR 1.54, 95% CI 1.30–1.83) and Impella (aOR 1.47, 95% CI 1.25–1.75) (all p<0.0001). Conclusions: In NIS 2016–2022, frailty was strongly and independently linked to higher in-hospital mortality, complications, and resource-intensive support among older NSTEMI patients undergoing PCI, supporting routine frailty-informed risk stratification and shared decision-making.", "source_page_url": "https://www.jscai.org/issue/S2772-9303(26)X2005-1", "status": "PASS", "text_source": "confex", "session_code": "OR1-9", "page_number": 104412 }, { "abstract_id": "OR1-10_104413", "title": "OR1-10 | Efficacy of Drug Coated Balloon Versus Drug Eluting Stent for De Novo Coronary Lesion: A Meta-analysis of Randomized Trials", "clean_title": "Efficacy of Drug Coated Balloon Versus Drug Eluting Stent for De Novo Coronary Lesion: A Meta-analysis of Randomized Trials", "conference": "Journal of the Society for Cardiovascular Angiography & Interventions", "conference_event": "SCAI 2026 Scientific Sessions (Montreal, April 23-26, 2026)", "doi_or_url": "https://doi.org/10.1016/j.jscai.2026.104413", "authors": [ "Parth Patel", "Aditya Desai", "Karnik Patel", "Maharshi Raval", "Poojan Prajapati", "Vaishvik Patel", "Nirmit Patel", "Waqas Ullah", "Said Ashraf" ], "publication_date": "2026-04", "full_text": "Background: Data on the efficacy of drug coated balloons (DCB) compared to drug eluting stents (DES) in de novo coronary lesions is evolving. Methods: We searched PubMed, Cochrane, and Embase through December 2025. 13 RCTs were included. Device-Oriented Composite Outcomes (DOCO) were defined as a composite of cardiovascular death, target-vessel MI (TV-MI), and target lesion revascularization (TLR). Prespecified subgroups included small vessel disease (diameter <3 mm) and STEMI. Pooled risk ratios (RR) with 95% confidence intervals (CI) were estimated using random-effects models. Results: DCB was associated with a significantly higher risk of DOCO (RR 1.58; 95% CI 1.07-2.33; P=0.02; I²=55%). No significant differences were found in cardiovascular mortality (RR 1.16; P=0.48), TV-MI (RR 1.09; P=0.61), MI (RR 0.89; P=0.36), stroke (RR 1.42; P=0.27), TLR (RR 1.07; P=0.83), and target vessel revascularization (RR 1.28; P=0.26). Paradoxically, DCB demonstrated superior angiographic efficacy, significantly reducing in-lesion late lumen loss compared to DES (MD -0.14; 95% CI -0.18 to -0.10; P<0.00001; I²=24%). Results were consistent across STEMI and small-vessel subgroups. Conclusions: Despite improved angiographic efficacy with reduced late lumen loss, DCB were associated with a higher risk of DOCO, supporting DES as the current standard of care while highlighting the need for further randomized trials to define the role of DCB in selected patient populations.", "source_page_url": "https://www.jscai.org/issue/S2772-9303(26)X2005-1", "status": "PASS", "text_source": "confex", "session_code": "OR1-10", "page_number": 104413 }, { "abstract_id": "OR1-12_104414", "title": "OR1-12 | Racial Disparities in Acute Coronary Syndrome Care and Outcomes Among Women: A Nationwide Analysis of Asian and White Patients", "clean_title": "Racial Disparities in Acute Coronary Syndrome Care and Outcomes Among Women: A Nationwide Analysis of Asian and White Patients", "conference": "Journal of the Society for Cardiovascular Angiography & Interventions", "conference_event": "SCAI 2026 Scientific Sessions (Montreal, April 23-26, 2026)", "doi_or_url": "https://doi.org/10.1016/j.jscai.2026.104414", "authors": [ "Sachin Prasad", "Daniel Moodey", "Shashank Gupta", "Mamdouh Souleymane", "Suryakumar Balasubramanian", "Rakendu J. Rajendran", "Anudeep Jala", "Ikhtesham Chaudhry", "Michael Lee", "Vincent Macolino", "Matthew Lee" ], "publication_date": "2026-04", "full_text": "Background Women with acute coronary syndrome (ACS) experience persistent disparities in diagnosis, treatment, and outcomes. While racial inequities in cardiovascular care are well documented, outcomes among Asian women with ACS remain underexplored, particularly with respect to invasive management and in-hospital mortality. Methods We queried the National Inpatient Sample (2018-2022), identifying women ≥18 years hospitalized with ACS. Patients were stratified by race, comparing Asian women(AW) and White women(WW). The primary outcome was in-hospital mortality. Secondary outcomes included receipt of percutaneous coronary intervention (PCI), cardiogenic shock, use of mechanical circulatory support (MCS), length of stay, and total hospitalization charges. Multivariate logistic regression was used to adjust for confounders and generate adjusted odds ratios (aOR). Results Among 1,307,285 female ACS admissions, 33,995 (2.7%) were AW. Compared with WW, AW had higher comorbidity burden (Charlson index 3.4 vs 3.0), higher prevalence of diabetes (58% vs 40%), and were more likely to reside in higher-income neighborhoods (88% vs 71%) (all p<0.005), with no significant age difference. After adjustment, AW had higher in-hospital mortality (aOR 1.16; 95% CI 1.04-1.29; p=0.007; 5.9% vs 4.5%) and lower odds of receiving PCI (aOR 0.86; 95% CI 0.81-0.91; p<0.005). They also experienced higher rates of cardiogenic shock (7.7% vs 5.6%) and greater use of MCS, including intra-aortic balloon pump (4.7% vs 2.9%) and Impella (1.7% vs 1.3%) (all p<0.05). AW had longer hospital stays (4.8 vs 4.2 days) and higher total charges ($132,908 vs $98,423) (p<0.005). Conclusions Despite higher socioeconomic status, AW hospitalized with ACS experienced higher mortality, lower rates of PCI, and greater hemodynamic instability requiring MCS compared with WW. These findings suggest inequities in invasive management and/or delayed recognition or escalation of care, contributing to more advanced presentation and worse outcomes. Improved understanding of biological, cultural, and system-level factors influencing ACS care in AW is critical to addressing these disparities and optimizing interventional treatment strategies.", "source_page_url": "https://www.jscai.org/issue/S2772-9303(26)X2005-1", "status": "PASS", "text_source": "confex", "session_code": "OR1-12", "page_number": 104414 }, { "abstract_id": "OR1-13_104415", "title": "OR1-13 | Cardiovascular Outcomes in SMuRF-less Acute Coronary Syndrome - A Large Database Analysis Using TriNetX", "clean_title": "Cardiovascular Outcomes in SMuRF-less Acute Coronary Syndrome - A Large Database Analysis Using TriNetX", "conference": "Journal of the Society for Cardiovascular Angiography & Interventions", "conference_event": "SCAI 2026 Scientific Sessions (Montreal, April 23-26, 2026)", "doi_or_url": "https://doi.org/10.1016/j.jscai.2026.104415", "authors": [ "Bala Pushparaji", "Parvathy Sankar", "Gokul Parameswaran", "Firas Anaya", "Sai Rahul Ponnana", "Santosh Kumar Sirasapalli", "Hritvik Jain", "Meera Kondapaneni", "Sanjay Rajagopalan" ], "publication_date": "2026-04", "full_text": "Background: Patients presenting with acute coronary syndromes (ACS) without standard modifiable cardiovascular risk factors (SMuRF-less: no hypertension, diabetes, hyperlipidemia, or smoking) represent a substantial minority of ACS presentations and paradoxically experience higher early mortality despite fewer traditional risk factors. Prior studies are largely non-US or single-system analyses, limiting generalizability. Large-scale validation of treatment patterns and outcomes in SMuRF-less ACS within a US population is lacking. Methods: We conducted a retrospective cohort study using the TriNetX Research Network, including adults hospitalized with a first ACS event (STEMI, NSTEMI, or unstable angina) between 2010–2024. SMuRF-less patients were compared with SMuRF-positive patients (≥1 risk factor). Propensity score matching (1:1) was performed for age, sex, and race. Primary outcomes included 30-day all-cause mortality and initiation of optimal medical therapy (ASA, P2Y12 inhibitor, beta-blocker (BB), ACE inhibitor/ARB) within 1 week. Secondary outcomes included 1-year mortality, revascularization (PCI/CABG) and cardiogenic shock during index hospitalization. Results: Among 665,643 ACS patients, 127,316 (19.1%) were SMuRF-less. After matching, 112,886 patients were included in each cohort. SMuRF-less patients had significantly higher 30-day mortality compared with SMuRF-positive patients (RR 1.39, p<0.001), along with lower rates of early medical therapy and revascularization. SMuRF-less patients consistently received less ASA (RR 0.73), P2Y12i (RR 0.72), statins (RR 0.72), BB (RR 0.71), ACEi/ARBs (RR 0.77), PCI (RR 0.11), and CABG (RR 0.10), but had lower risk of cardiogenic shock (RR 0.51). At 1 year, mortality rates were comparable between groups (RR 0.99, p=0.9537), suggesting late hazard normalization. Conclusions: In a large US EHR-based cohort, SMuRF-less ACS patients experience excess early mortality associated with lower use of optimal medical therapy and revascularization, despite similar 1-year mortality. These findings highlight a critical early treatment gap and underscore the need for improved recognition and aggressive early management of this unique population.", "source_page_url": "https://www.jscai.org/issue/S2772-9303(26)X2005-1", "status": "PASS", "text_source": "confex", "session_code": "OR1-13", "page_number": 104415 }, { "abstract_id": "OR1-14_104416", "title": "OR1-14 | End of Aspirin Era? Early Withdrawal vs Continuation of Dual Antiplatelet Therapy after PCI in Acute Coronary Syndrome: A Meta-Analysis of Randomized Trials", "clean_title": "End of Aspirin Era? Early Withdrawal vs Continuation of Dual Antiplatelet Therapy after PCI in Acute Coronary Syndrome: A Meta-Analysis of Randomized Trials", "conference": "Journal of the Society for Cardiovascular Angiography & Interventions", "conference_event": "SCAI 2026 Scientific Sessions (Montreal, April 23-26, 2026)", "doi_or_url": "https://doi.org/10.1016/j.jscai.2026.104416", "authors": [ "Abdalhakim Shubietah", "Mohamed S. Elgendy", "Mohamed Saad Rakab", "Elsayed Balbaa", "Ahmed Emara", "Belal Mohamed Hamed", "Qasem Salah", "Anas Odeh", "Hamza A. Abdul-Hafez", "Ameer Awashra", "Mohamed Abuelazm", "Ariel Katz", "Rocio Barriga Guzman", "Mohammed Mhanna", "Mohammed Ruzieh" ], "publication_date": "2026-04", "full_text": "Background: The benefit-risk profile of early aspirin discontinuation followed by P2Y12-inhibitor monotherapy versus continued dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) remains uncertain. Objectives: To compare early aspirin discontinuation with P2Y12-inhibitor monotherapy versus continued DAPT after PCI for ACS. Methods: We searched PubMed, Scopus, Web of Science, and Embase for eligible RCTs up to September 2025. Risk ratios (RRs) were pooled using a random-effects model, and trial sequential analysis assessed conclusiveness (PROSPERO: CRD420251151605). Results: A total of 33,292 participants from 10 RCTs were included. P2Y12-inhibitor monotherapy significantly reduced major (BARC 3/5: 1.2% vs 2.4%; RR 0.47; 95% CI 0.37–0.60) and clinically relevant bleeding (BARC 2–5: 2.4% vs 5.3%; RR 0.45; 95% CI 0.39–0.53), with no difference in myocardial infarction (1.79% vs 1.59%; RR 1.13; 95% CI 0.95–1.34) or all-cause mortality (1.40% vs 1.49%; RR 0.97; 95% CI 0.77–1.22). TSA showed conclusive benefit for bleeding (BARC 2–5 and 3–5), while a 25% relative reduction in MI or all-cause mortality was unlikely. Subgroup results were consistent regardless of aspirin discontinuation timing (before 1 month, at 1–2 months, or at 3 months). Ticagrelor monotherapy reduced mortality vs DAPT (1.15% vs 1.48%; RR 0.78), while other agents showed no difference. Conclusions: After ACS-PCI, early aspirin discontinuation with P2Y12-inhibitor monotherapy reduces bleeding without raising ischemic risk. A mortality benefit with ticagrelor warrants confirmation in larger RCTs.", "source_page_url": "https://www.jscai.org/issue/S2772-9303(26)X2005-1", "status": "PASS", "text_source": "confex", "session_code": "OR1-14", "page_number": 104416 }, { "abstract_id": "OR1-15_104417", "title": "OR1-15 | Insurance Status and In-Hospital Outcomes After Percutaneous Coronary Intervention: A Nationwide Analysis (2016–2021)", "clean_title": "Insurance Status and In-Hospital Outcomes After Percutaneous Coronary Intervention: A Nationwide Analysis (2016–2021)", "conference": "Journal of the Society for Cardiovascular Angiography & Interventions", "conference_event": "SCAI 2026 Scientific Sessions (Montreal, April 23-26, 2026)", "doi_or_url": "https://doi.org/10.1016/j.jscai.2026.104417", "authors": [ "Samuel Sule-SAA", "Charles Poluyi", "Rebecca Kotei", "Johannes Gelan", "Mark Ntow", "Mugtaba Ahmed", "Anoma Barua", "Esther Duodo", "Melisaa Brace", "Olawoye Adedoyin", "Kalpana Panigrahi", "Ajibola Adedayo", "Shivani Verma" ], "publication_date": "2026-04", "full_text": "Background Insurance-related disparities persist in cardiovascular care. We evaluated the association between payer status and in-hospital mortality and major complications after percutaneous coronary intervention (PCI) in the US. Methods We conducted a retrospective cohort study using the National Inpatient Sample 2016–2021. PCI hospitalizations were stratified by insurance: Private (reference), Medicare, Medicaid, and Uninsured. The primary outcome was in-hospital mortality. Secondary outcomes included procedural and post-PCI complications. Multivariable models adjusted for demographics, Charlson Comorbidity Index, and hospital characteristics. Results Among 2,470,079 PCI hospitalizations, 4.6% were uninsured. Adjusted in-hospital mortality was high compared to private insurance: Medicare AOR 1.10 (95% CI 1.03–1.16), Medicaid AOR 1.40 (95% CI 1.28–1.52), uninsured AOR 1.92 (95% CI 1.72–2.12); p<0.01 for all. Uninsured patients also had higher adjusted odds of cardiogenic shock (AOR 1.35), AKI (AOR 1.25), ventricular arrhythmia (AOR 1.14) and cardiac arrest (AOR 1.14). Procedural complication rates (hematoma, bleeding, coronary dissection, type 4 MI) did not differ by payer. Conclusions Insurance status is an independent predictor of post-PCI mortality, with uninsured patients facing nearly double the odds of death. The absence of differences in procedural complications, suggests that disparities arise from systemic factors including delayed presentation, disease severity, or post-procedural care rather than procedural quality. Policy interventions are essential to ensure equitable revascularization outcomes.\nAuthor\nSamuel Sule-SAA, MBBS\nOne Brooklyn Health System", "source_page_url": "https://www.jscai.org/issue/S2772-9303(26)X2005-1", "status": "PASS", "text_source": "confex", "session_code": "OR1-15", "page_number": 104417 }, { "abstract_id": "OR1-16_104418", "title": "OR1-16 | The Rise of the Algorithmic Co-Operator: A Systematic Review of Artificial Intelligence as a Real-Time Partner in Interventional Cardiology", "clean_title": "The Rise of the Algorithmic Co-Operator: A Systematic Review of Artificial Intelligence as a Real-Time Partner in Interventional Cardiology", "conference": "Journal of the Society for Cardiovascular Angiography & Interventions", "conference_event": "SCAI 2026 Scientific Sessions (Montreal, April 23-26, 2026)", "doi_or_url": "https://doi.org/10.1016/j.jscai.2026.104418", "authors": [ "Ishita Vasudev", "Akinchan Bhardwaj", "Rushil Vasudev" ], "publication_date": "2026-04", "full_text": "Background Interventional cardiology is increasingly adopting artificial intelligence (AI) for real-time procedural support, particularly for imaging interpretation, device guidance and risk stratification. However, evidence for clinical impact and generalizability remains limited. Methods We systematically searched peer-reviewed studies (2021–2025) evaluating real-time AI in interventional cardiology across procedural guidance, imaging interpretation, complication prediction and intraprocedural support. Study design, AI modality, clinical setting and outcomes were extracted and synthesized qualitatively due to heterogeneity. Results We included 20 studies evaluating real-time AI in coronary and structural interventions. Deep learning models achieved high accuracy for intravascular imaging interpretation, including near real time optical coherence tomography plaque analysis (~0.07 seconds per frame) and automated identification of lipid-rich plaque, fibrous cap thickness, reducing interobserver variability. AI-guided procedural tools reduced contrast use by approximately 25–30% and decreased fluoroscopy time without compromising procedural success. AI-assisted robotic navigation improved catheter precision and reduced operator radiation exposure. ML-based risk models modestly outperformed traditional scores for bleeding and composite adverse events, but showed only minor gains for mortality prediction and short-term outcomes after transcatheter valve interventions. Overall, AI improved surrogate metrics more consistently than clinical endpoints and most studies lacked prospective validation. Conclusions Real-time AI shows promise for improving imaging, decision-making, and procedural efficiency, but evidence is largely retrospective and single-center, with persistent concerns about data quality, transparency and generalizability. Prospective multicenter validation is needed to establish clinical benefit.", "source_page_url": "https://www.jscai.org/issue/S2772-9303(26)X2005-1", "status": "PASS", "text_source": "confex", "session_code": "OR1-16", "page_number": 104418 }, { "abstract_id": "OR1-17_104419", "title": "OR1-17 | Temporal Trends and Outcomes of Coronary Artery Perforation During Percutaneous Coronary Intervention: A Nationwide Analysis", "clean_title": "Temporal Trends and Outcomes of Coronary Artery Perforation During Percutaneous Coronary Intervention: A Nationwide Analysis", "conference": "Journal of the Society for Cardiovascular Angiography & Interventions", "conference_event": "SCAI 2026 Scientific Sessions (Montreal, April 23-26, 2026)", "doi_or_url": "https://doi.org/10.1016/j.jscai.2026.104419", "authors": [ "Magdi Zordok", "Michael S. Megaly" ], "publication_date": "2026-04", "full_text": "Background: Coronary artery perforation (CAP) is a rare but potentially catastrophic complication of percutaneous coronary intervention (PCI), occurring most often during complex procedures. Although prior studies suggest higher CAP rates among older and female patients, contemporary national data—particularly regarding outcomes associated with cardiac tamponade (CT)—remain limited. Methods: Using the Nationwide Readmissions Database (January 2016–December 2022), we identified PCI procedures complicated by CAP using ICD-10 codes. Temporal trends, clinical characteristics, management strategies, and outcomes were compared between patients with and without CAP, and among CAP patients with and without CT. Results: Among 1,716,983 PCI procedures, 6,207 (0.36%) were complicated by CAP, with increasing incidence over time (0.30% in Q1 2016 vs. 0.34% in Q4 2022; p=0.001). Of CAP patients, 1,495 (24.1%) developed CT, with a rising proportion over time (64.1% in early 2016 vs. 74.3% in late 2022; p<0.001). Compared with CAP patients without CT, those with CT were older (median 72 [IQR 63–79] vs. 66 [57–75] years) and more frequently female (42.1% vs. 32.5%) (both p<0.001). CT patients had higher rates of atrial fibrillation/flutter and end-stage renal disease and were more likely to present with STEMI (38.9% vs. 28.3%; p<0.001). Hemodynamic instability was pronounced, with cardiogenic shock in 41.4%. Mechanical circulatory support was used more frequently (35.1% vs. 5.7%), including Impella, VA-ECMO, and intra-aortic balloon pump support (all p<0.001). CABG occurred more often in CT patients (6.5% vs. 0.6%; p<0.001). Among CT patients requiring pericardiocentesis (n=1,514), in-hospital mortality was 25.0%, 16.6% were discharged to a facility, and 18.3% required urgent 30-day readmission. Major complications included bleeding requiring transfusion (29.3%), ventricular tachycardia (12.1%), stroke (2.3%), and dialysis-requiring acute kidney injury (3.8%). Conclusions: CAP during PCI is increasingly frequent and associated with severe morbidity and mortality, particularly when complicated by cardiac tamponade. Early recognition and rapid multidisciplinary management are essential in contemporary PCI practice.", "source_page_url": "https://www.jscai.org/issue/S2772-9303(26)X2005-1", "status": "PASS", "text_source": "confex", "session_code": "OR1-17", "page_number": 104419 }, { "abstract_id": "OR1-18_104420", "title": "OR1-18 | Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Patients Undergoing PCI on Dual Antiplatelet Therapy", "clean_title": "Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Patients Undergoing PCI on Dual Antiplatelet Therapy", "conference": "Journal of the Society for Cardiovascular Angiography & Interventions", "conference_event": "SCAI 2026 Scientific Sessions (Montreal, April 23-26, 2026)", "doi_or_url": "https://doi.org/10.1016/j.jscai.2026.104420", "authors": [ "Zafer Akman", "Ishmum Chowdhury", "Kuan-Yu Chi", "Pei-Lun Lee", "Chidubem Ezenna", "Sridhar Mangalesh", "Armin Nouri", "Raiza Rossi", "Abdulla A. Damluji", "Michael G. Nanna" ], "publication_date": "2026-04", "full_text": "Selective serotonin reuptake inhibitors (SSRIs) are commonly used in patients with coronary artery disease. Because SSRIs impair platelet aggregation, their use with dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) may increase bleeding risk.", "source_page_url": "https://www.jscai.org/issue/S2772-9303(26)X2005-1", "status": "PARTIAL", "text_source": "openalex", "session_code": "OR1-18", "page_number": 104420 }, { "abstract_id": "OR1-19_104421", "title": "OR1-19 | Comparative Outcomes of Acoramidis vs Tafamidis Therapy in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)", "clean_title": "Comparative Outcomes of Acoramidis vs Tafamidis Therapy in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)", "conference": "Journal of the Society for Cardiovascular Angiography & Interventions", "conference_event": "SCAI 2026 Scientific Sessions (Montreal, April 23-26, 2026)", "doi_or_url": "https://doi.org/10.1016/j.jscai.2026.104421", "authors": [ "Sultana Jahan", "Haidar Hajeh", "Mustafa Al-Mollah", "Varun Victor", "Seliman Ali", "Muhammad Burhan", "M Chadi Alraies" ], "publication_date": "2026-04", "full_text": "Background Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive infiltrative disorder with limited disease-modifying therapies. Acoramidis is a next-generation transthyretin stabilizer designed to enhance tetramer stabilization compared with tafamidis, real world outcome is limited. Methods Adults with ATTR-CM treated with acoramidis or tafamidis were identified using the TriNetX Global Collaborative Network. Propensity-score matching yielded 286 balanced pairs. Outcomes at 6 and 9 months included a composite of heart failure exacerbation (HFE), acute myocardial infarction, cardiac arrest, ventricular tachycardia/fibrillation, or stroke, as well as hospitalizations, atrial fibrillation/flutter, ventricular arrhythmias, acute kidney injury (AKI), and dizziness/syncope. Results At 6 months, acoramidis was associated with a lower composite event risk than tafamidis (18.2% vs 29.0%; 95% CI 0.46–0.85; p=0.002). Acoramidis also reduced hospitalizations (22.7% vs 34.3%; 95% CI, 0.51–0.87; p=0.002), HFE (7.7% vs 14.0%; 95% CI, 0.34–0.90; p=0.02), atrial fibrillation/flutter (41.3% vs 53.1%; 95% CI (0.65, 0.93); p=0.004), ventricular arrhythmias (5.6% vs 11.5%; 95% CI (0.27, 0.86); p=0.01), and AKI (9.1% vs 16.1%; 95% CI, (0.36, 0.89) ; p=0.01), with no difference in dizziness/syncope. At 9 months, benefits persisted, including a lower composite outcome and continued reductions in hospitalizations, HF exacerbations, arrhythmias, and AKI. Conclusions Acoramidis was associated with significantly lower cardiovascular and renal events than tafamidis at 6 and 9 months, supporting further prospective evaluation.", "source_page_url": "https://www.jscai.org/issue/S2772-9303(26)X2005-1", "status": "PASS", "text_source": "confex", "session_code": "OR1-19", "page_number": 104421 }, { "abstract_id": "OR1-20_104422", "title": "OR1-20 | Sweet but Not Safe? Circulating Polyols and Cardiovascular Risk: A Systematic Review and Meta-Analysis", "clean_title": "Sweet but Not Safe? Circulating Polyols and Cardiovascular Risk: A Systematic Review and Meta-Analysis", "conference": "Journal of the Society for Cardiovascular Angiography & Interventions", "conference_event": "SCAI 2026 Scientific Sessions (Montreal, April 23-26, 2026)", "doi_or_url": "https://doi.org/10.1016/j.jscai.2026.104422", "authors": [ "Anirudh Jain", "Evani Jain", "Khalid Elhassan", "Omesh Prathiraja", "Javeria Naz", "Erin Williams", "Michael abdul-Malek", "Hassaan Imtiaz" ], "publication_date": "2026-04", "full_text": "Background: Dietary polyols (sugar alcohols) are ubiquitous in sugar-free products, but their cardiovascular safety is debated. Reported risk estimates vary widely; a comprehensive pooled analysis clarifying sources of heterogeneity is lacking. Methods: We performed a PRISMA 2020 systematic review/meta-analysis (PubMed, MEDLINE, Embase, Cochrane Library, Web of Science, and Google Scholar to October 2025). Random-effects models estimated pooled hazard ratios (HRs) for cardiovascular events from studies measuring circulating polyol blood levels. Heterogeneity was examined by polyol type. Leave-one-out sensitivity analysis assessed robustness. Publication bias assessment was not performed due to limited studies (<10). Results: Six blood biomarker studies (24,259 patients) were included. High circulating polyol levels were associated with a 65% increased cardiovascular risk (HR 1.65, 95% CI 1.40-1.95) with remarkable consistency (I²=0.0%). Risk was significant across all polyols: erythritol (HR 1.87, 1.46-2.39), xylitol (HR 1.57, 1.12-2.21), and sorbitol/mannitol (HR 1.42, 1.05-1.91). Sensitivity analysis confirmed robustness (HR range 1.61-1.76 excluding each study). Conclusions: High circulating blood levels of common dietary polyols are associated with a consistent, robust 65% increased cardiovascular risk. This first comprehensive meta-analysis of blood biomarker data warrants urgent re-evaluation of the GRAS status of these widely consumed sweeteners.", "source_page_url": "https://www.jscai.org/issue/S2772-9303(26)X2005-1", "status": "PASS", "text_source": "confex", "session_code": "OR1-20", "page_number": 104422 }, { "abstract_id": "OR1-22_104423", "title": "OR1-22 | Impact of SGLT2 Inhibitors on Post-PCI Outcomes in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease: A Propensity Matched Analysis", "clean_title": "Impact of SGLT2 Inhibitors on Post-PCI Outcomes in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease: A Propensity Matched Analysis", "conference": "Journal of the Society for Cardiovascular Angiography & Interventions", "conference_event": "SCAI 2026 Scientific Sessions (Montreal, April 23-26, 2026)", "doi_or_url": "https://doi.org/10.1016/j.jscai.2026.104423", "authors": [ "Abdul-Rahaman Adedolapo Ottun", "Efeturi M. Okorigba", "Baffour Otchere", "Prince K. Darko", "God-dowell O. Odukudu", "Ayodeji Adeolu Akinmeji", "Emmanuel Nyamekye Ansah", "Zavion Edwards" ], "publication_date": "2026-04", "full_text": "Background Patients with type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) who undergo percutaneous coronary intervention (PCI) have increased adverse outcomes. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated cardiovascular benefits in heart failure and diabetic populations, but their impact on post-PCI outcomes remains insufficiently characterized . This study evaluates the association between SGLT2 inhibitor use and cardiovascular outcomes following PCI in patients with T2DM and CAD. Methods This retrospective cohort study utilized the TriNetX US Collaborative Network database, Adult patients (≥18 years) with T2DM and CAD who underwent PCI between January 2014 and December 2023 were identified. Patients were stratified into two cohorts: SGLT2 inhibitor users and non-users . Propensity score matching was performed for demographics, comorbidities, medications, and laboratory values, yielding 28,316 matched pairs. Primary outcome was all-cause mortality. Secondary outcomes included 3P MACE(3-point major adverse cardiovascular events), acute myocardial infarction, repeat revascularization (PCI/CABG),. Kaplan-Meier survival analysis with log-rank testing and Cox proportional hazards modeling were employed. Results After propensity matching, SGLT2 inhibitor use was associated with decreased all-cause mortality ( HR: 0.521, 95% CI: 0.491-0.552, p<0.001), lower rates of 3P MACE ( HR: 0.654, 95% CI: 0.636-0.671, p<0.001) ,acute myocardial infarction (HR: 0.646, 95% CI: 0.628-0.666, p<0.001), and repeat revascularization procedures (HR: 0.609, 95% CI: 0.579-0.640, p<0.001) Conclusions In this real-world analysis of patients with T2DM and CAD undergoing PCI, SGLT2 inhibitor use was associated with reductions in all-cause mortality, 3P MACE, myocardial infarction, and repeat revascularization procedures at one-year follow-up. These findings suggest that SGLT2 inhibitors confer significant cardiovascular protective effects in this high-risk population . The comprehensive benefits observed across multiple cardiovascular endpoints support the use of SGLT2 inhibitors for secondary prevention in these groups and warrant further randomised studies.", "source_page_url": "https://www.jscai.org/issue/S2772-9303(26)X2005-1", "status": "PASS", "text_source": "confex", "session_code": "OR1-22", "page_number": 104423 } ]